TechFlow news, July 7 — Aditxt, Inc. (Nasdaq: ADTX), a U.S.-listed company, today announced the launch of its bitXbio™ initiative, an innovative financial strategy combining Bitcoin reserves with equity financing. The program aims to support the company's biotechnology commercialization efforts, particularly targeting potential monetization events in 2026, including the planned IPO of its subsidiary Pearsanta.
Aditxt currently operates two projects focused on autoimmune diseases and early disease detection, and will establish a Bitcoin reserve based on funding availability while strategically utilizing its existing equity financing capacity of approximately $125 million. CEO Amro Albanna stated that this move will help strengthen Aditxt's balance sheet and enhance corporate value, creating greater value for shareholders.
